CAPR - Capricor Therapeutics, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
1.38
0.00 (0.00%)
As of 12:37PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close1.38
Open1.35
Bid1.36 x 1300
Ask1.38 x 800
Day's range1.35 - 1.41
52-week range0.63 - 4.25
Volume86,826
Avg. volume230,356
Market cap40.172M
Beta2.01
PE ratio (TTM)16.24
EPS (TTM)0.09
Earnings date8 Aug 2018 - 13 Aug 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.80
Trade prices are not sourced from all markets
  • Should You Be Holding Capricor Therapeutics Inc (NASDAQ:CAPR)?
    Simply Wall St.2 days ago

    Should You Be Holding Capricor Therapeutics Inc (NASDAQ:CAPR)?

    Capricor Therapeutics Inc (NASDAQ:CAPR) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In theRead More...

  • Does Capricor Therapeutics Inc’s (NASDAQ:CAPR) PE Ratio Warrant A Buy?
    Simply Wall St.21 days ago

    Does Capricor Therapeutics Inc’s (NASDAQ:CAPR) PE Ratio Warrant A Buy?

    Capricor Therapeutics Inc (NASDAQ:CAPR) is currently trading at a trailing P/E of 13.4x, which is lower than the industry average of 25.8x. While this makes CAPR appear like a greatRead More...

  • Associated Presslast month

    Capricor: 1Q Earnings Snapshot

    On a per-share basis, the Beverly Hills, California-based company said it had a loss of 14 cents. The biotechnology company posted revenue of $400,100 in the period. Its adjusted revenue was $400,000. ...

  • Associated Press3 months ago

    Capricor posts 4Q profit

    On a per-share basis, the Beverly Hills, California-based company said it had net income of 42 cents. Losses, adjusted for non-recurring gains, were 11 cents per share. The biotechnology company posted ...

  • Associated Press7 months ago

    Capricor reports 3Q loss

    The Beverly Hills, California-based company said it had a loss of 12 cents per share. The biotechnology company posted revenue of $313,300 in the period. Its adjusted revenue was $313,000. In the final ...

  • Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session
    Zacks9 months ago

    Capricor Therapeutics (CAPR) Looks Good: Stock Adds 13.9% in Session

    Capricor Therapeutics (CAPR) was a big mover last session, as the company saw its shares rise almost 14% on the day amid huge volumes.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes